FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

The FDA has approved Yeztugo, a twice-yearly HIV injection by Gilead shown to virtually eliminate new infections.

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

The FDA approved Yeztugo (lenacapavir), a twice-yearly injection that prevents HIV with up to 99.9% effectiveness, showing ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention ...